Merck Global Health Innovation Fund

MSD Global Health Innovation Fund (MGHIF) is the corporate venture capital arm of Merck & Co., founded in 2010 and based in Rahway, New Jersey. It is a growth investor partnering with innovative digital health and data science companies that facilitate and optimize biopharmaceutical operations, with the goal of improving patient care. Beyond the core fund, MSD also runs a separate Impact Venture Fund, supporting the development of innovative medicines and health interventions in low- and middle-income countries, having reached over 1 million people through health interventions via its impact investments in 2024 alone. MGHIF's focus spans digital health, drug discovery, manufacturing, supply chain, information technology, and AI/ML applications in healthcare, investing from seed through Series C stages. With 130 investments and 42 exits recorded, and 214 co-investor relationships, the fund maintains one of the more active and long-running corporate venture portfolios in the healthcare sector. MGHIF's investment approach leverages its position within a global biopharmaceutical company to identify and support technologies capable of directly optimizing operations across the pharmaceutical value chain, from drug discovery through manufacturing and patient-facing digital health solutions.